THE GOVERNMENT OF THE UNITED STATES OF AMERICA ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OFHEALTH AND HUMAN SERVICES
发明人:
申请号：
NZ59526206
公开号：
NZ595262A
申请日:
2006.08.30
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
Disclosed is the use of an IL-23 antagonist for the preparation of a pharmaceutical composition for the treatment of an autoimmune ocular inflammatory disease (AOID) in a patient, wherein the IL-23 antagonist is a monoclonal antibody or a monoclonal 5 antibody fragment, wherein the IL-23 antagonist binds to and inhibits the activity of IL-23p19 or IL-23R.
